Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 54

1.

Protein kinase C inhibitors override ZEB1-induced chemoresistance in HCC.

Sreekumar R, Emaduddin M, Al-Saihati H, Moutasim K, Chan J, Spampinato M, Bhome R, Yuen HM, Mescoli C, Vitale A, Cillo U, Rugge M, Primrose J, Hilal MA, Thirdborough S, Tulchinsky E, Thomas G, Mirnezami A, Sayan AE.

Cell Death Dis. 2019 Sep 23;10(10):703. doi: 10.1038/s41419-019-1885-6.

2.

ZEB1 and IL-6/11-STAT3 signalling cooperate to define invasive potential of pancreatic cancer cells via differential regulation of the expression of S100 proteins.

Al-Ismaeel Q, Neal CP, Al-Mahmoodi H, Almutairi Z, Al-Shamarti I, Straatman K, Jaunbocus N, Irvine A, Issa E, Moreman C, Dennison AR, Emre Sayan A, McDearmid J, Greaves P, Tulchinsky E, Kriajevska M.

Br J Cancer. 2019 Jul;121(1):65-75. doi: 10.1038/s41416-019-0483-9. Epub 2019 May 24.

3.

An FBXW7-ZEB2 axis links EMT and tumour microenvironment to promote colorectal cancer stem cells and chemoresistance.

Li N, Babaei-Jadidi R, Lorenzi F, Spencer-Dene B, Clarke P, Domingo E, Tulchinsky E, Vries RGJ, Kerr D, Pan Y, He Y, Bates DO, Tomlinson I, Clevers H, Nateri AS.

Oncogenesis. 2019 Feb 19;8(3):13. doi: 10.1038/s41389-019-0125-3.

4.

Assessment of Nuclear ZEB2 as a Biomarker for Colorectal Cancer Outcome and TNM Risk Stratification.

Sreekumar R, Harris S, Moutasim K, DeMateos R, Patel A, Emo K, White S, Yagci T, Tulchinsky E, Thomas G, Primrose JN, Sayan AE, Mirnezami AH.

JAMA Netw Open. 2018 Oct 5;1(6):e183115. doi: 10.1001/jamanetworkopen.2018.3115.

5.

EMT: A mechanism for escape from EGFR-targeted therapy in lung cancer.

Tulchinsky E, Demidov O, Kriajevska M, Barlev NA, Imyanitov E.

Biochim Biophys Acta Rev Cancer. 2019 Jan;1871(1):29-39. doi: 10.1016/j.bbcan.2018.10.003. Epub 2018 Nov 10. Review.

PMID:
30419315
6.

Erratum: Actin-binding protein alpha-actinin 4 (ACTN4) is a transcriptional co-activator of RelA/p65 sub-unit of NF-kB.

Aksenova V, Turoverova L, Khotin M, Magnusson KE, Tulchinsky E, Melino G, Pinaev GP, Barlev N, Tentler D.

Oncotarget. 2018 Sep 28;9(76):34450. doi: 10.18632/oncotarget.26206. eCollection 2018 Sep 28.

7.

Short stretches of rare codons regulate translation of the transcription factor ZEB2 in cancer cells.

Wan Makhtar WR, Browne G, Karountzos A, Stevens C, Alghamdi Y, Bottrill AR, Mistry S, Smith E, Bushel M, Pringle JH, Sayan AE, Tulchinsky E.

Oncogene. 2017 Nov 23;36(47):6640-6648. doi: 10.1038/onc.2017.273. Epub 2017 Aug 7.

8.

Colorectal cancer cells use the negative feedback regulators of WNT signalling to activate epithelial-mesenchymal transition pathways.

Tulchinsky E.

Gut. 2017 Apr;66(4):563-564. doi: 10.1136/gutjnl-2016-313185. Epub 2017 Jan 12. No abstract available.

PMID:
28082317
9.

The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma.

Ramsdale R, Jorissen RN, Li FZ, Al-Obaidi S, Ward T, Sheppard KE, Bukczynska PE, Young RJ, Boyle SE, Shackleton M, Bollag G, Long GV, Tulchinsky E, Rizos H, Pearson RB, McArthur GA, Dhillon AS, Ferrao PT.

Sci Signal. 2015 Aug 18;8(390):ra82. doi: 10.1126/scisignal.aab1111.

PMID:
26286024
10.

PR55α-containing protein phosphatase 2A complexes promote cancer cell migration and invasion through regulation of AP-1 transcriptional activity.

Gilan O, Diesch J, Amalia M, Jastrzebski K, Chueh AC, Verrills NM, Pearson RB, Mariadason JM, Tulchinsky E, Hannan RD, Dhillon AS.

Oncogene. 2015 Mar 5;34(10):1340. doi: 10.1038/onc.2014.460. No abstract available.

PMID:
25740609
11.

FRA-1 as a driver of tumour heterogeneity: a nexus between oncogenes and embryonic signalling pathways in cancer.

Dhillon AS, Tulchinsky E.

Oncogene. 2015 Aug 20;34(34):4421-8. doi: 10.1038/onc.2014.374. Epub 2014 Nov 10. Review.

12.

Widespread FRA1-dependent control of mesenchymal transdifferentiation programs in colorectal cancer cells.

Diesch J, Sanij E, Gilan O, Love C, Tran H, Fleming NI, Ellul J, Amalia M, Haviv I, Pearson RB, Tulchinsky E, Mariadason JM, Sieber OM, Hannan RD, Dhillon AS.

PLoS One. 2014 Mar 21;9(3):e88950. doi: 10.1371/journal.pone.0088950. eCollection 2014.

13.

PR55α-containing protein phosphatase 2A complexes promote cancer cell migration and invasion through regulation of AP-1 transcriptional activity.

Gilan O, Diesch J, Amalia M, Jastrzebski K, Chueh AC, Verrills NM, Pearson RB, Mariadason JM, Tulchinsky E, Hannan RD, Dhillon AS.

Oncogene. 2015 Mar 5;34(10):1333-9. doi: 10.1038/onc.2014.26. Epub 2014 Mar 17. Erratum in: Oncogene. 2015 Mar 5;34(10):1340.

PMID:
24632621
14.

Plasticity of melanoma and EMT-TF reprogramming.

Tulchinsky E, Pringle JH, Caramel J, Ansieau S.

Oncotarget. 2014 Jan 15;5(1):1-2. No abstract available.

15.

A switch in the expression of embryonic EMT-inducers drives the development of malignant melanoma.

Caramel J, Papadogeorgakis E, Hill L, Browne GJ, Richard G, Wierinckx A, Saldanha G, Osborne J, Hutchinson P, Tse G, Lachuer J, Puisieux A, Pringle JH, Ansieau S, Tulchinsky E.

Cancer Cell. 2013 Oct 14;24(4):466-80. doi: 10.1016/j.ccr.2013.08.018. Epub 2013 Sep 26.

16.

Actin-binding protein alpha-actinin 4 (ACTN4) is a transcriptional co-activator of RelA/p65 sub-unit of NF-kB.

Aksenova V, Turoverova L, Khotin M, Magnusson KE, Tulchinsky E, Melino G, Pinaev GP, Barlev N, Tentler D.

Oncotarget. 2013 Feb;4(2):362-72. Erratum in: Oncotarget. 2018 Sep 28;9(76):34450.

17.

ZEB/miR-200 feedback loop: at the crossroads of signal transduction in cancer.

Hill L, Browne G, Tulchinsky E.

Int J Cancer. 2013 Feb 15;132(4):745-54. doi: 10.1002/ijc.27708. Epub 2012 Jul 21. Review.

18.

Reactive oxygen species and mitochondrial sensitivity to oxidative stress determine induction of cancer cell death by p21.

Masgras I, Carrera S, de Verdier PJ, Brennan P, Majid A, Makhtar W, Tulchinsky E, Jones GD, Roninson IB, Macip S.

J Biol Chem. 2012 Mar 23;287(13):9845-54. doi: 10.1074/jbc.M111.250357. Epub 2012 Feb 6.

19.

A 19S proteasomal subunit cooperates with an ERK MAPK-regulated degron to regulate accumulation of Fra-1 in tumour cells.

Pakay JL, Diesch J, Gilan O, Yip YY, Sayan E, Kolch W, Mariadason JM, Hannan RD, Tulchinsky E, Dhillon AS.

Oncogene. 2012 Apr 5;31(14):1817-24. doi: 10.1038/onc.2011.375. Epub 2011 Aug 29.

PMID:
21874050
20.

Fra-1 controls motility of bladder cancer cells via transcriptional upregulation of the receptor tyrosine kinase AXL.

Sayan AE, Stanford R, Vickery R, Grigorenko E, Diesch J, Kulbicki K, Edwards R, Pal R, Greaves P, Jariel-Encontre I, Piechaczyk M, Kriajevska M, Mellon JK, Dhillon AS, Tulchinsky E.

Oncogene. 2012 Mar 22;31(12):1493-503. doi: 10.1038/onc.2011.336. Epub 2011 Aug 8.

PMID:
21822309

Supplemental Content

Loading ...
Support Center